Acetylcysteine In Diabetes (AID): A randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics

    loading  Checking for direct PDF access through Ovid



Patients with diabetes mellitus (DM) are at increased risk of contrast-associated nephropathy irrespective of their baseline creatinine (Cr). We tested the efficacy of N-acetylcysteine (NAC) relative to hydration in unselected patients (irrespective of baseline Cr) with DM.


We conducted a randomized open-label study comparing hydration alone (combined oral and rapid intravenous hydration, n = 69) to NAC plus hydration (similar hydration protocol plus NAC 600 mg BID × 4 doses, n = 68) in diabetic patients (mean age 65 ± 10 years, 65% men) undergoing elective coronary angiography. The primary end point was the mean change in serum Cr measured up to 96 hours postangiography.


Baseline Cr was 1.14 ± 0.43 mg/dL (Cr ≥1.3 mg/dL in 37 subjects). Baseline characteristics including blood urea nitrogen, Cr, and contrast volume were similar between the 2 groups. The mean Cr change in the NAC group was 0.14 ± 0.47 versus 0.08 ± 0.11 mg/dL in the hydration only group (P = NS). Contrast-associated nephropathy, defined as a ≥0.5 mg/dL increase in Cr, was significantly more common in the NAC group, 9.2% versus 1.4%, P = .043. Similar results were found in the subgroup of participants with either an increased baseline serum Cr (≥1.3 mg/dL) or in those receiving high contrast volumes (>100 mL).


N-Acetylcysteine provides no benefit over an aggressive hydration protocol in patients with DM undergoing coronary angiography.

Related Topics

    loading  Loading Related Articles